14-Aminocamptothecins: Their Synthesis, Preclinical Activity, and Potential Use for Cancer Treatment

被引:20
作者
Duan, Jian-Xin [1 ]
Cai, Xiaohong [1 ]
Meng, Fanying [1 ]
Sun, Jessica D. [1 ]
Liu, Qian [1 ]
Jung, Donald [1 ]
Jiao, Hailong [1 ]
Matteucci, Jackson [1 ]
Jung, Brian [1 ]
Bhupathi, Deepthi [1 ]
Ahluwalia, Dharmendra [1 ]
Huang, Heli [1 ]
Hart, Charles P. [1 ]
Matteucci, Mark [1 ]
机构
[1] Threshold Pharmaceut, Redwood City, CA 94063 USA
关键词
TOPOISOMERASE-I INHIBITORS; PLANT ANTITUMOR AGENTS; CAMPTOTHECIN DERIVATIVES; HUMAN BLOOD; RESISTANCE; TOPOTECAN; DRUG; 9-AMINO-20(S)-CAMPTOTHECIN; PROTEINS; ANALOGS;
D O I
10.1021/jm101354u
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
14-Aminocamptothecins were synthesized in good yields by treating camptothecin (1a) and 7-ethylcamptothecin (1b) with 90% fuming nitric acid either neat or in acetic anhydride and then followed by I reduction of the resulting 14-nitrocamptothecins (2). 14-Aminocamptothecin (3a) and 7-ethyl-14-aminocamptothecin (313) demonstrated excellent cytotoxic potency against human tumor cell lines in vitro, and they are not substrates for any of the major clinically relevant efflux pumps (MDR1, MRP1, and BCRP). 3a and 3b showed similar cytotoxicity against human and mouse bone marrow progenitor cells. This is in contrast to many camptothecin analogues, which are substrates for efflux pumps and are dramatically more toxic to human marrow cells relative to murine. 3a and 3b demonstrated significant brain penetration when dosed orally in mice. 3b showed significantly better efficacy relative to topotecan when dosed orally in the three ectopic xenograft models, H460, HT29, and PC-3. On the basis of its favorable in vitro and in vivo profile, 3b warrants future development.
引用
收藏
页码:1715 / 1723
页数:9
相关论文
共 30 条
[1]  
AVGEROPOULOS GN, 1999, ONCOLOGIST, V4, P209
[2]   Role of transport proteins in drug absorption, distribution and excretion [J].
Ayrton, A ;
Morgan, P .
XENOBIOTICA, 2001, 31 (8-9) :469-497
[3]   Novel camptothecin derivatives as topoisomerase I inhibitors [J].
Basili, Serena ;
Moro, Stefano .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (05) :555-574
[4]   THE IMPORTANT ROLE OF ALBUMIN IN DETERMINING THE RELATIVE HUMAN BLOOD STABILITIES OF THE CAMPTOTHECIN ANTICANCER DRUGS [J].
BURKE, TG ;
MUNSHI, CB ;
MI, ZH ;
JIANG, Y .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (04) :518-519
[5]  
CAO Z, 1996, J CHEM SOC P1, V21, P2629
[6]   Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro [J].
EricksonMiller, CL ;
May, RD ;
Tomaszewski, J ;
Osborn, B ;
Murphy, MJ ;
Page, JG ;
Parchment, RE .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (05) :467-472
[7]   Topoisomerase I inhibitors for the treatment of brain tumors [J].
Feun, Lynn ;
Savaraj, Niramol .
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (05) :707-716
[8]  
GIOVANELLA BC, 1991, CANCER RES, V51, P3052
[9]  
HARKER WG, 1985, CANCER RES, V45, P4091
[10]   MODIFICATION OF THE HYDROXY LACTONE RING OF CAMPTOTHECIN - INHIBITION OF MAMMALIAN TOPOISOMERASE-I AND BIOLOGICAL-ACTIVITY [J].
HERTZBERG, RP ;
CARANFA, MJ ;
HOLDEN, KG ;
JAKAS, DR ;
GALLAGHER, G ;
MATTERN, MR ;
MONG, SM ;
BARTUS, JO ;
JOHNSON, RK ;
KINGSBURY, WD .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (03) :715-720